Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor beta, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

Ferry Eskens, N Steeghs, Jaap Verweij, JL Bloem, O Christensen, L van Doorn, J Ouwerkerk, Maja de Jonge, JWR Nortier, J Kraetzschmar, P Rajagopalan, H Gelderblom

Research output: Contribution to journalArticleAcademicpeer-review

44 Citations (Scopus)

Abstract

Purpose Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-beta, and c-Kit. This phase I dose escalation study was conducted to evaluate the safety and tolerability of telatinib, with additional pharmacokinetic, pharmacodynamic, and efficacy assessments. Patients and Methods Patients with solid tumors refractory to standard therapies or with no standard therapy available were enrolled. Doses of continuously administered telatinib were escalated from 20 mg once daily to 1,500 mg twice daily. Results Fifty-three patients were enrolled. Most frequently observed drug-related adverse events were nausea (26.4%; grade >= 3, 0%) and hypertension (20.8%; grade 3, 11.3%; grade 4, 0%). Two dose-limiting toxicities were observed: one poorly controlled hypertension (600 mg twice daily), and one grade 2 weight loss, anorexia, and fatigue (1,500 mg twice daily). A formal maximum-tolerated dose was not reached. Telatinib was rapidly absorbed, with median time to peak concentration (t(max)) lower than 3 hours after dose. A nearly dose-proportional increase in exposure was observed with substantial variability. Telatinib half-life averaged 5.5 hours. Biomarker analyses showed dose-dependent increase in VEGF levels and decrease in plasma soluble VEGFR-2 levels, with a plateau at 900 mg twice daily. A decrease in tumor blood flow (K-trans and IAUC(60)) was observed with dynamic contrast-enhanced magnetic resonance imaging. Best tumor response was stable disease, observed in 50.9% of patients. Conclusion Telatinib was safe and well tolerated up to 1,500 mg twice daily. Based on pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase II studies.
Original languageUndefined/Unknown
Pages (from-to)4169-4176
Number of pages8
JournalJournal of Clinical Oncology
Volume27
Issue number25
DOIs
Publication statusPublished - 2009

Cite this